A Prognostic Clinicopathologic Classification of Pituitary Endocrine Tumors

被引:29
作者
Raverot, Gerald [1 ,2 ,3 ]
Vasiljevic, Alexandre [1 ,2 ,4 ]
Jouanneau, Emmanuel [1 ,2 ,5 ]
Trouillas, Jacqueline [1 ,2 ,4 ]
机构
[1] CNRS, INSERM, Lyon Neurosci Res Ctr, Neurooncol & NeuroInflammat Team,U1028,UMR5292, F-69372 Lyon, France
[2] Univ Lyon 1, F-69372 Lyon, France
[3] Hosp Civils Lyon, Grp Hosp Est, Dept Endocrinol, F-69677 Bron, France
[4] Grp Hosp Est, Dept Pathol, F-69677 Bron, France
[5] Grp Hosp Est, Dept Neurosurg, F-69677 Bron, France
关键词
Classification; Pituitary endocrine tumor; Pathologic markers; POSTOPERATIVE FOLLOW-UP; CLINICAL CHARACTERISTICS; TEMOZOLOMIDE TREATMENT; ADENOMAS; CARCINOMAS; MANAGEMENT; INVASION; GROWTH; AGGRESSIVENESS; PROLIFERATION;
D O I
10.1016/j.ecl.2014.10.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary endocrine tumors are considered as benign. However, clinical and pathological data favor their consideration as more than an endocrinological disease. Using data from a retrospective case-control study of 410 patients, with 8 years of follow-up, the authors have validated a new clinicopathologic classification of pituitary tumors. This classification is based on tumor size, immunohistochemical type, and grade based on the assessment of invasion and proliferation, and it provides a prognostic value for predicting postoperative disease-free outcome or recurrence/ progression status. This classification aids the identification of patients presenting with pituitary tumors that have a high risk of recurrence and enable construction of personalized therapies.
引用
收藏
页码:11 / +
页数:9
相关论文
共 37 条
[1]   Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently [J].
Bradley, KJ ;
Wass, JAH ;
Turner, HE .
CLINICAL ENDOCRINOLOGY, 2003, 58 (01) :59-64
[2]   Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies [J].
Chinezu, Laura ;
Vasiljevic, Alexandre ;
Jouanneau, Emmanuel ;
Francois, Patrick ;
Borda, Angela ;
Trouillas, Jacqueline ;
Raverot, Gerald .
HUMAN PATHOLOGY, 2014, 45 (01) :71-77
[3]   Silent GH pituitary tumor: Diagnostic and therapeutic challenges [J].
Chinezu, Laura ;
Jouanneau, Emmanuel ;
Vasiljevic, Alexandre ;
Trouillas, Jacqueline ;
Raverot, Gerald .
ANNALES D ENDOCRINOLOGIE, 2013, 74 (5-6) :491-495
[4]   Silent corticogonadotroph adenomas: Clinical and cellular characteristics and long-term outcomes [J].
Cooper O. ;
Ben-Shlomo A. ;
Bonert V. ;
Bannykh S. ;
Mirocha J. ;
Melmed S. .
Hormones and Cancer, 2010, 1 (2) :80-92
[5]  
DeLellis RA, 2004, WHO CLASSIFICATION T, P10
[6]   Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study [J].
Delgrange, E ;
Trouillas, J ;
Maiter, D ;
Donckier, J ;
Tourniaire, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2102-2107
[7]   Pituitary Carcinoma with Malignant Growth from First Presentation and Fulminant Clinical Course-Case Report and Review of the Literature [J].
Dudziak, Katarzyna ;
Honegger, Juergen ;
Bornemann, Antje ;
Horger, Marius ;
Muessig, Karsten .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (09) :2665-2669
[8]   Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly [J].
Fougner, Stine Lyngvi ;
Casar-Borota, Olivera ;
Heck, Ansgar ;
Berg, Jens Petter ;
Bollerslev, Jens .
CLINICAL ENDOCRINOLOGY, 2012, 76 (01) :96-102
[9]   The 2004 World health organization classification of pituitary tumors: is it clinically helpful? [J].
Grossman, AB .
ACTA NEUROPATHOLOGICA, 2006, 111 (01) :76-77
[10]   What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics [J].
Gurlek, Alper ;
Karavitaki, Niki ;
Ansorge, Olaf ;
Wass, John A. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 156 (02) :143-153